Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Literature DB >> 29703727

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

David A Sallman¹, Jason Brayer², Elizabeth M Sagatys³, Caroline Lonez⁴, Eytan Breman⁴, Sophie Agaugué⁴, Bikash Verma⁵, David E Gilham⁴, Frédéric F Lehmann⁴, Marco L Davila⁶.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29703727 PMCID： PMC6119132 DOI： 10.3324/haematol.2017.186742

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

18 in total

Review 1. Roles of the NKG2D immunoreceptor and its ligands.

Authors: David H Raulet
Journal: Nat Rev Immunol Date: 2003-10 Impact factor: 53.106

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

Review 3. Advances in NKG2D ligand recognition and responses by NK cells.

Authors: Nina Le Bert; Stephan Gasser
Journal: Immunol Cell Biol Date: 2014-01-21 Impact factor: 5.126

4. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Authors: David S Ritchie; Paul J Neeson; Amit Khot; Stefan Peinert; Tsin Tai; Kellie Tainton; Karen Chen; Mandy Shin; Dominic M Wall; Dirk Hönemann; Peter Gambell; David A Westerman; Javier Haurat; Jennifer A Westwood; Andrew M Scott; Lucy Kravets; Michael Dickinson; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Michael H Kershaw; H Miles Prince
Journal: Mol Ther Date: 2013-07-08 Impact factor: 11.454

Review 5. NKG2D ligands as therapeutic targets.

Authors: Paul Spear; Ming-Ru Wu; Marie-Louise Sentman; Charles L Sentman
Journal: Cancer Immun Date: 2013-05-01

6. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Authors: Cor H J Lamers; Ralph Willemsen; Pascal van Elzakker; Sabine van Steenbergen-Langeveld; Marieke Broertjes; Jeannette Oosterwijk-Wakka; Egbert Oosterwijk; Stefan Sleijfer; Reno Debets; Jan W Gratama
Journal: Blood Date: 2010-10-01 Impact factor: 22.113

Review 7. Toxicities of chimeric antigen receptor T cells: recognition and management.

Authors: Jennifer N Brudno; James N Kochenderfer
Journal: Blood Date: 2016-05-20 Impact factor: 22.113

8. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.

Authors: Quan-shun Wang; Yao Wang; Hai-yan Lv; Qing-wang Han; Hui Fan; Bo Guo; Li-li Wang; Wei-dong Han
Journal: Mol Ther Date: 2014-09-01 Impact factor: 11.454

Review 9. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

Authors: Armen Mardiros; Stephen J Forman; Lihua E Budde
Journal: Curr Opin Hematol Date: 2015-11 Impact factor: 3.284

10. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Authors: Xiaoran Zhang; Aparana Rao; Paola Sette; Christopher Deibert; Alexander Pomerantz; Wi Jin Kim; Gary Kohanbash; Yigang Chang; Yongseok Park; Johnathan Engh; Jaehyuk Choi; Timothy Chan; Hideho Okada; Michael Lotze; Paola Grandi; Nduka Amankulor
Journal: Neuro Oncol Date: 2016-04-25 Impact factor: 12.300

21 in total

Review 1. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors: Premal D Lulla; Maksim Mamonkin; Malcolm K Brenner
Journal: Cancer J Date: 2019 May/Jun Impact factor: 3.360

2. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors: Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal: Cancer Immunol Res Date: 2018-11-05 Impact factor: 11.151

Review 3. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors: Longzhen Cui; Yan Liu; Yifan Pang; Tingting Qian; Liang Quan; Zhiheng Cheng; Yifeng Dai; Xu Ye; Ying Pang; Jinlong Shi; Xiaoyan Ke; Depei Wu; Lin Fu
Journal: Cancer Gene Ther Date: 2019-07-11 Impact factor: 5.987

Review 4. Progress on CAR-T cell therapy for hematological malignancies.

Authors: Kejia Hu; Yue Huang; Yongxian Hu; He Huang
Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban Date: 2022-04-25

5. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.

Authors: Hui Zhang; Chaoke Bu; Zhiyong Peng; Guangchao Li; Zhao Zhou; Wen Ding; Yongwei Zheng; Yingyi He; Zhengbin Hu; Kunlin Pei; Min Luo; Chunfu Li
Journal: Leukemia Date: 2022-09-23 Impact factor: 12.883

10. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.

Authors: Yu-Yang Ng; Johan C K Tay; Zhendong Li; Junjian Wang; Jiangqing Zhu; Shu Wang
Journal: Mol Ther Date: 2020-09-05 Impact factor: 11.454